Alexandria T. Phan, MD | Authors

Stanford Health Care

14251 Winchester Blvd

94301

Articles

Neuroendocrine Tumors: Novel Approaches in the Age of Targeted Therapy

December 02, 2008

One hundred years after Oberndorfer coined the word “carcinoid,” neuroendocrine tumors (NETs) are thought to be rare tumors characterized by the capacity for hormone production and often an indolent course. Recent data from population-based registries have shown a significant rise in the diagnosed incidence of NETs over the past 3 decades.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas

August 01, 2002

Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.